EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dendritic Cell-Derived Exosomes in Cancer Immunotherapy

Shumin Luo, Jing Chen, Fang Xu, Huan Chen, Yiru Li, Weihua Li

Pharmaceutics · 01.08.2023 · 15 (8) · 2070

DOI: 10.3390/pharmaceutics15082070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.08.2023. Verfasst von Shumin Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Beijing, National Natural Science Foundation of China, High-Level Public Health Technical Talents Project of Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exosomes are nanoscale vesicles released by diverse types of cells for complex intercellular communication. Numerous studies have shown that exosomes can regulate the body’s immune response to tumor cells and interfere with the tumor microenvironment (TME). In clinical trials on dendritic cell (DC)-based antitumor vaccines, no satisfactory results have been achieved. However, recent studies suggested that DC-derived exosomes (DEXs) may be superior to DC-based antitumor vaccines in avoiding tumor cell-mediated immunosuppression. DEXs contain multiple DC-derived surface markers that capture tumor-associated antigens (TAAs) and promote immune cell-dependent tumor rejection. These findings indicate the necessity of the further development and improvement of DEX-based cell-free vaccines to complement chemotherapy, radiotherapy, and other immunotherapies. In this review, we highlighted the recent progress of DEXs in cancer immunotherapy, particularly by concentrating on landmark studies and the biological characterization of DEXs, and we summarized their important role in the tumor immune microenvironment (TIME) and clinical application in targeted cancer immunotherapy. This review could enhance comprehension of advances in cancer immunotherapy and contribute to the elucidation of how DEXs regulate the TIME, thereby providing a reference for utilizing DEX-based vaccines in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

cancerdendritic cellsexosomesimmunotherapy

Autor:innen und Institutionen

  • Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Integrated Chinese and Western Medicine Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Förderung

  • the Natural Science Foundation of Beijing
  • National Natural Science Foundation of China
  • High-Level Public Health Technical Talents Project of Beijing
  • Medical Institutes Public Welfare Development and Reform Pilot Project of Beijing
  • Natural Science Foundation of Beijing
  • Beijing Municipal Institute of Public Medical Research Development and Reform Pilot Project

Zitieren

APA

Luo, S., Chen, J., Xu, F., Chen, H., Li, Y., & Li, W. (2023). Dendritic Cell-Derived Exosomes in Cancer Immunotherapy. Pharmaceutics, 15(8), 2070. https://doi.org/10.3390/pharmaceutics15082070

Vancouver

Luo S, Chen J, Xu F, Chen H, Li Y, Li W. Dendritic Cell-Derived Exosomes in Cancer Immunotherapy. Pharmaceutics. 2023;15(8):2070. doi:10.3390/pharmaceutics15082070

BibTeX
@article{Luo2023,
  author = {Luo, Shumin and Chen, Jing and Xu, Fang and Chen, Huan and Li, Yiru and Li, Weihua},
  title = {Dendritic Cell-Derived Exosomes in Cancer Immunotherapy},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2070},
  doi = {10.3390/pharmaceutics15082070}
}
Kostenlos starten →